| 期刊論文1. | Fingeret, M. C.、Vidrine, D. J.、Reece, G. P.、Gillenwater, A. M.、Gritz, E. R.(2010)。Multidimensional analysis of body image concerns among newly diagnosed patients with oral cavity cancer。Head & Neck,32(3),301-309。 | 2. | Annunziata, M. A.、Giovannini, L.、Muzzatti, B.(2012)。Assessing the body image: Relevance, application and instruments for oncological settings。Supportive Care in Cancer,20(5),901-907。 | 3. | Barankin, B.、DeKoven, J.(2002)。Psychosocial effect of common skin diseases。Canadian Family Physician,48,712-716。 | 4. | Bezjak, A.、Tu, D.、Seymour, L.、Clark, G.、Trajkovic, A.、Zukin, M.、Shepherd, F. A.(2006)。Symptom improvement in lung cancer patients treated with erlotinib: Quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21。Journal of Clinical Oncology,24(24),3831-3837。 | 5. | Fingeret, M. C.、Yuan, Y.、Urbauer, D.、Weston, J.、Nipomnick, S.、Weber, R.(2011)。The nature and extent of body image concerns among surgically treated patients with head and neck cancer。Psycho-Oncology,21(8),836-844。 | 6. | Galimont-Collen, A. F. S.、Vos, L. E.、Lavrijsen, A. P. M.、Ouwerkerk, J.、Gelderblom, H.(2007)。Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors。European Journal of Cancer,43(5),845-851。 | 7. | Grande, R.、Narducci, F.、Bianchetti, S.、Mansueto, G.、Gemma, D.、Sperduti, I.、Gamucci, T.(2013)。Pre-emptive skin toxicity treatment for anti-EGFR drugs: Evaluation of efficacy of skin moisturizers and lymecycline. A phase II study。Supportive Care in Cancer,21(6),1691-1695。 | 8. | Hellgren, E. M.、Lagergren, P.、Larsson, A. C.、Schandl, A. R.、Sackey, P. V.(2013)。Body image and psychological outcome after severe skin and soft tissue infection requiring intensive care。Acta Anaesthesiologica Scandinavica,57(2),220-228。 | 9. | Jatoi, A.、Nguyen, P. L.(2008)。Do patients die from rashes from epidermal growth factor receptor inhibitors? A systematic review to help counsel patients about holding therapy。The Oncologist,13(11),1201-1204。 | 10. | Joshi, S. S.、Ortiz, S.、Witherspoon, J. N.、Rademaker, A.、West, D. P.、Anderson, R.、Lacouture, M. E.(2010)。Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life。Cancer,116(16),3916-3923。 | 11. | King, M. T.、Kenny, P.、Shiell, A.、Hall, J.、Boyages, J.(2000)。Quality of life three months and one year after first treatment for early stage breast cancer: Influence of treatment and patient characteristics。Quality of Life Research,9(7),789-800。 | 12. | Lacouture, M. E.、Anadkat, M. J.、Bensadoun, R. J.、Bryce, J.、Chan, A.、Epstein, J. B.、Murphy, B. A.(2011)。Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities。Supportive Care in Cancer,19(8),1079-1095。 | 13. | Li, T.、Perez-Soler, R.(2009)。Skin toxicities associated with epidermal growth factor receptor inhibitors。Targeted Oncology,4(2),107-119。 | 14. | Melosky, B.(2012)。Supportive care treatments for toxicities of anti-EGFR and other targeted agents。Current Oncology,19(1),59-63。 | 15. | Mok, T. S.、Wu, Y. L.、Thongprasert, S.、Yang, C. H.、Chu, D. T.、Saijo, N.、Fukuoka, M.(2009)。Gefitinib or carboplatin- paclitaxel in pulmonary adenocarcinoma。New England Journal of Medicine,361(10),947-957。 | 16. | Perez-Soler, R.、Saltz, L.(2005)。Cutaneous adverse effects with HER1/EGFR-targeted agents: Is there a silver lining?。Journal of Clinical Oncology,23(22),5235-5246。 | 17. | Rosell, R.、Carcereny, E.、Gervais, R.、Vergnenegre, A.、Massuti, B.、Felip, E.、Paz-Ares, L.(2012)。Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-smallcell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial。The Lancet Oncology,13(3),239-246。 | 18. | Rumsey, N.、Clarke, A.、White, P.、Wyn-Williams, M.、Garlick, W.(2004)。Altered body image: Appearance-related concerns of people with visible disfigurement。Journal of Advanced Nursing,48(5),443-453。 | 19. | Wagner, L. I.、Lacouture, M. E.(2007)。Dermatologic toxicities associated with EGFR inhibitors: Dermatologic toxicities associated with EGFR inhibitors: The clinical psychologist’s perspective. Impact on health-related quality of life and implications for clinical management of psychological sequelae。Oncology (Williston Park,21(11),34-36。 | 20. | White, K. J.、Roydhouse, J. K.(2011)。Psychosocial impact of cutaneous toxicities associated with epidermal growth factor receptor-inhibitor treatment。Clinical Journal of Oncology Nursing,15(1),88-96。 | 21. | Price, B.(1990)。A model for body-image care。Journal of Advanced Nursing,15(5),585-593。 | 研究報告1. | 衛生福利部統計處(2013)。民國100 年度衛生統計動向--死因統計。 延伸查詢 | 學位論文1. | 林如玉(2009)。接受標靶治療之肺癌病患的副作用及其與皮膚相關生活品質探討(碩士論文)。臺灣大學。 延伸查詢 | 圖書1. | Schilder, Paul(1970)。The image and appearance of the human body。New York, NY:International Universities Press。 | 其他1. | 中央健康保險署(2013)。全民健康保險藥品給付規定第9 節抗癌瘤藥物,http://www.nhi.gov.tw/webdata/webdata.aspx?menu=21&menu_id=713&WD_ID=849&webdata_id=2919。 延伸查詢 | 2. | National Comprehensive Cancer Network(2013)。Distress management version 2,http://www.nccn.org/professionals/physician_gls/pdf/distress.pdf。 | 3. | US National Institutes of Health and National Cancer Institute(2009)。Common terminology criteria for adverse events,http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf。 | 圖書論文1. | Bandura, Albert(1994)。Self-efficacy。Encyclopedia of human behavior。New York:Academic Press。 | |
| |